针对心血管事件的向抗炎疗法:挑战和机遇
Tianyi Ma1, Ling Wang1, Xiaorong Yan1
1Shigatse Branch, Xinqiao Hospital, Third Military Medical University, Shigatse, China.
Journal of clinical hypertension (Greenwich, Conn.)
|November 19, 2025
概括
针对性抗炎药物,如IL-1β抑制剂和胆固醇,通过解决炎症,显示出减少心血管事件的希望. 这些疗法提供了一种新方法,与传统治疗心血管疾病 (CVD) 一起进行治疗.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 炎症是动脉样硬化和心血管事件的关键因素.
- 传统的心血管疾病治疗不能完全解决炎症成分.
研究的目的:
- 审查针对心血管疾病的新型向抗炎疗法的疗效和安全性.
- 探索这些药物在减轻心血管风险方面的潜力.
主要方法:
- 对抗炎症疗法的新兴证据的审查.
- 对干白素 (IL) - 1β 抑制剂 (例如,卡纳基努马布) 的研究分析.
- 在心血管病患者中检查菌素的疗效.
- 考虑针对IL-6和瘤亡因子-α的新兴疗法.
主要成果:
- 在心肌梗塞后的患者中,卡纳基努马布证明了主要心血管不良事件 (MACE) 的减少,而不依赖脂质水平.
- 在患有慢性冠状动脉疾病和最近心肌梗塞的患者中,素在减少心血管事件方面表现出有效性.
- 目前正在进行的研究正在调查其他炎症媒介,如IL-6和TNF-α.
结论:
- 向性抗炎疗法是传统心血管疾病治疗的有希望的补充.
- 这些新的疗法有可能彻底改变心血管事件管理.
- 需要进一步的研究来优化患者选择,长期安全性和成本效益.
相关概念视频
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Rheumatic Heart Disease III: Medical Management
268
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
268
Inflammatory Bowel Disease IV: Pharmacological Management
452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
452


